|
1
|
Wulfken LM, Moritz R, Ohlmann C,
Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brünagel
G, von Ruecker A, Müller SC and Ellinger J: MicroRNAs in renal cell
carcinoma: Diagnostic implications of serum miR-1233 levels. PLoS
One. 6:e257872011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cho E, Adami HO and Lindblad P:
Epidemiology of renal cell cancer. Hematol Oncol Clin North Am.
25:651–665. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Keefe SM, Nathanson KL and Rathmell WK:
The molecular biology of renal cell carcinoma. Semin Oncol.
40:421–428. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cairns P: Renal cell carcinoma. Cancer
Biomark. 9:461–473. 2010.
|
|
6
|
Koscianska E, Baev V, Skreka K, Oikonomaki
K, Rusinov V, Tabler M and Kalantidis K: Prediction and preliminary
validation of oncogene regulation by miRNAs. BMC Mol Biol.
8:792007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schmidt U and Begley CG: Cancer diagnosis
and microarrays. Int J Biochem Cell Biol. 35:119–124. 2003.
View Article : Google Scholar
|
|
8
|
Yu X, Zhang X, Bi T, Ding Y, Zhao J, Wang
C, Jia T, Han D, Guo G, Wang B, et al: MiRNA expression signature
for potentially predicting the prognosis of ovarian serous
carcinoma. Tumour Biol. 34:3501–3508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Walter BA, Valera VA, Pinto PA and Merino
MJ: Comprehensive microRNA profiling of prostate cancer. J Cancer.
4:350–357. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Osanto S, Qin Y, Buermans HP, Berkers J,
Lerut E, Goeman JJ and van Poppel H: Genome-wide microRNA
expression analysis of clear cell renal cell carcinoma by next
generation deep sequencing. PLoS One. 7:e382982012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aqeilan RI, Calin GA and Croce CM: miR-15a
and miR-16-1 in cancer: Discovery, function and future
perspectives. Cell Death Differ. 17:215–220. 2010. View Article : Google Scholar
|
|
12
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: Oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar
|
|
14
|
Sun Y, Shen S, Tang H, Xiang J, Peng Y,
Tang A, Li N, Zhou W, Wang Z, Zhang D, Xiang B, et al: miR-429
identified by dynamic transcriptome analysis is a new candidate
biomarker for colorectal cancer prognosis. OMICS. 18:54–64. 2014.
View Article : Google Scholar :
|
|
15
|
Sun T, Wang C, Xing J and Wu D: miR-429
modulates the expression of c-myc in human gastric carcinoma cells.
Eur J Cancer. 47:2552–2559. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Y, Li M, Zang W, Ma Y, Wang N, Li P,
Wang T and Zhao G: MiR-429 up-regulation induces apoptosis and
suppresses invasion by targeting Bcl-2 and SP-1 in esophageal
carcinoma. Cell Oncol (Dordr). 36:385–394. 2013. View Article : Google Scholar
|
|
17
|
Zhu W, He J, Chen D, Zhang B, Xu L, Ma H,
Liu X, Zhang Y and Le H: Expression of miR-29c, miR-93, and miR-429
as potential biomarkers for detection of early stage non-small lung
cancer. PLoS One. 9:e877802014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim
JH, Kim JW and Kim S: MicroRNA expression profiles in serous
ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Levine RJ: An IRB-approved protocol on the
use of human fetal tissue. IRB. 11:7–8. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yoon S and De Micheli G: Prediction of
regulatory modules comprising microRNAs and target genes.
Bioinformatics. 21(Suppl 2): ii93–ii100. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Gu J, Roth JA, Hildebrandt MA,
Lippman SM, Ye Y, Minna JD and Wu X: Pathway-based serum microRNA
profiling and survival in patients with advanced stage non-small
cell lung cancer. Cancer Res. 73:4801–4809. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu D, Pan H, Zhou Y, Zhou J, Fan Y and Qu
P: microRNA-133b downregulation and inhibition of cell
proliferation, migration and invasion by targeting matrix
metallopeptidase-9 in renal cell carcinoma. Mol Med Rep.
9:2491–2498. 2014.PubMed/NCBI
|
|
23
|
Mangolini A, Bonon A, Volinia S, Lanza G,
Gambari R, Pinton P, Russo GR, Del Senno L, Dell'Atti L and Aguiari
G: Differential expression of microRNA501-5p affects the
aggressiveness of clear cell renal carcinoma. FEBS Open Bio.
4:952–965. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vergho D, Kneitz S, Rosenwald A, Scherer
C, Spahn M, Burger M, Riedmiller H and Kneitz B: Combination of
expression levels of miR-21 and miR-126 is associated with
cancer-specific survival in clear-cell renal cell carcinoma. BMC
Cancer. 14:252014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang T, Niu X, Liao L, Cho EA and Yang H:
The contributions of HIF-target genes to tumor growth in RCC. PLoS
One. 8:e805442013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Choueiri TK, Fay AP, Gagnon R, Lin Y,
Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL,
Carpenter C, et al: The role of aberrant VHL/HIF pathway elements
in predicting clinical outcome to pazopanib therapy in patients
with metastatic clear-cell renal cell carcinoma. Clin Cancer Res.
19:5218–5226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Conti A, Santoni M, Amantini C, Burattini
L, Berardi R, Santoni G, Cascinu S and Muzzonigro G: Progress of
molecular targeted therapies for advanced renal cell carcinoma.
Biomed Res Int. 2013:4191762013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gupta S and Spiess PE: The prospects of
pazopanib in advanced renal cell carcinoma. Ther Adv Urol.
5:223–232. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang SW, Chang WH, Su YC, Chen YC, Lai YH,
Wu PT, Hsu CI, Lin WC, Lai MK and Lin JY: MYC pathway is activated
in clear cell renal cell carcinoma and essential for proliferation
of clear cell renal cell carcinoma cells. Cancer Lett. 273:35–43.
2009. View Article : Google Scholar
|
